Contact

Pipeline

Nostopharma repurposes approved Hh inhibitors. In mouse models of non-hereditary HO, Hh blockade significantly reduced HO formation.

PIPELINE STRATEGY

Balanced portfolio, de-risked execution

Nostopharma prioritizes programs with clear biomarkers, scalable manufacturing, and partnership-ready commercialization paths.

Our partners:

Preclinical
NP104G
Therapeutic Area: Acquired form of HO:

Advanced preclinical candidate in preclinical development.

Proof of Concept
EctoBone Patch™
Therapeutic area-Genetic form of HO:

subcutaneous delivery via microneedles

Preclinical
NP102
Therapeutic area: Genetic and acquired form of HO:

localized delivery with sustained release.